MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review-past, present and future

Journal of Gastrointestinal Oncology 2016 February [Link]

Dehal A, Smith JJ, Nash GM.

Abstract

Peritoneal carcinomatosis (PC) has historically been considered a terminal condition with merely palliative treatment achieving a survival rate measured in months. Cytoreductive surgery (CyRS) and intraperitoneal chemotherapy (IPC) have emerged as potentially effective regional treatments with the potential for long-term survival in well-selected patients. The fundamentals of CyRS and IPC are patient selection and complete cytoreduction. Since there is now sufficient evidence for the superiority of CyRS and IPC to systemic chemotherapy alone in a highly select group of patients, surgeons and oncologists should be aware of this modality as a potential benefit for patients with PC. The aim of this report is to highlight cancer-specific evidence in the context of ongoing studies regarding the outcome of this treatment.

Both comments and trackbacks are currently closed.